The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2009

Filed:

Mar. 20, 2006
Applicants:

Heather Janelle Barbosa, Indianapolis, IN (US);

Elizabeth Aaron Collins, Edinburgh, IN (US);

Chafiq Hamdouchi, Carmel, IN (US);

Erik James Hembre, Indianapolis, IN (US);

Philip Arthur Hipskind, New Palestine, IN (US);

Richard Duane Johnston, Greenfield, IN (US);

Jianliang LU, Fishers, IN (US);

Michael John Rupp, Indianapolis, IN (US);

Takako Takakuwa, Indianapolis, IN (US);

Richard Craig Thompson, Frankfort, IN (US);

Inventors:

Heather Janelle Barbosa, Indianapolis, IN (US);

Elizabeth Aaron Collins, Edinburgh, IN (US);

Chafiq Hamdouchi, Carmel, IN (US);

Erik James Hembre, Indianapolis, IN (US);

Philip Arthur Hipskind, New Palestine, IN (US);

Richard Duane Johnston, Greenfield, IN (US);

Jianliang Lu, Fishers, IN (US);

Michael John Rupp, Indianapolis, IN (US);

Takako Takakuwa, Indianapolis, IN (US);

Richard Craig Thompson, Frankfort, IN (US);

Assignee:

Eli Lilly and Company, Indianapolis, IN (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 487/04 (2006.01); A61K 31/5355 (2006.01); A61K 31/5025 (2006.01); A61K 31/541 (2006.01); A61P 25/24 (2006.01); A61P 25/22 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07D 279/12 (2006.01); C07D 295/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.


Find Patent Forward Citations

Loading…